Home › Oncolytics Biotech's REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer
 

Keywords :   


Oncolytics Biotech's REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

2015-02-17 15:06:44| Biotech - Topix.net

Oncolytics Biotech Inc. , a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation for its lead product candidate, REOLYSIN, for the treatment of pancreatic cancer. "This is the second indication for which we have received Orphan Drug Designation in the United States," said Dr. Brad Thompson, President and CEO of Oncolytics.

Tags: treatment drug cancer receives

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05China hits back at US and EU as trade rows deepen
20.05How should countries deal with falling birth rates?
20.05Eastern North Pacific Tropical Weather Outlook
20.05Atlantic Tropical Weather Outlook
20.05Water investors have withdrawn billions, says research
19.05Atlantic Tropical Weather Outlook
19.05Eastern North Pacific Tropical Weather Outlook
19.05IT Cosmetics and Kenvue Launch New Products
More »